Novavax has publicly proclaimed: “No human fetal-derived cell lines or tissue, including HEK293 cells, are used in the development, manufacture or production of the Novavax COVID-19 vaccine candidate, NVX-CoV2373.”
HEK293 is not the only human fetal cell line. It is rather suspicious that Novavax would specifically cite that particular cell line and claim that it was not used in the “development, manufacture or production” of its COVID-19 vaccine when it turns out that Novavax, indeed, used that very cell line when “testing” the efficacy of its vaccine. Is not testing part of the development of the vaccine? Absolutely!
It seems that Novavax has been caught in a subtle deception. It is more properly described as a bald-faced lie. Novavax funded research that studied the efficacy and safety of their COVID-19 vaccine. That study expressly states that it involved the use of “human embryonic kidney (HEK) 293F cells.”
When presented with that damning evidence, Novavax claimed that it “did not use HEK293 cells in the testing of NVX-CoV2373.” Novavax, apparently, understood that testing was part of the development of its COVID-19 vaccine and decided to deny that it used the aborted fetal cell line of HEK293 in its testing.
But that statement from Novavax denying that it used aborted fetal cells in testing its COVID-19 vaccine was later impeached by a letter sent by Novavax to the Charlotte Lozier Institute, wherein Novavax officially admitted:
It seems that Novavax is pathological in its deception. In the same letter sent by Novavax to the Charlotte Lozier Institute where it admitted that its vaccine was tested on aborted fetal tissue, Novavax stated that “fetal-derived cell lines were not used in the manufacture, testing, or production of the Novavax COVID-19 vaccine.”
“Oh what a tangled web we weave when first we practice to deceive.”
The Inova Hospital System is spreading the Novavax lie. Indeed, the Inova imprimatur of the Novavaz vaccine includes the provably false statement that “no human fetal-derived cell lines or tissues are contained in the Novavax COVID-19 vaccine, adjuvanted, or used in the development, manufacture, or release testing.”
Release testing is something that is done after the release of a product. Apparently, Novavax is now quibbling that they did not test their product on aborted fetal cells after the product was released. I guess they hope that will be enough to pull the wool of the eye of most who will not realize that Novavax, in fact, tested their COVID-19 vaccine on aborted fetal cells before releasing it.
On June 9, 2022, Liberty Counsel documented that Novavax is lying about its claim that no fetal cells were used in the development and manufacturing of their vaccine. Below is the post from Liberty Counsel:
Despite erroneous claims that Novavax’s COVID-19 injection (NVX-CoV2373) does not have any connection to abortion-derived cell lines, evidence from Novavax’s own published study shows otherwise.
While Novavax claims that no human fetal-derived cell lines or tissue, including HEK293 cells, were used in the development, manufacture, or production of the Novavax COVID-19 shots, it is not true that there is no association with abortion because an aborted fetal cell line was used in the testing phase of Novavax.
Novavax’s published study, “Structural Analysis of Full-Length SARS-CoV-2 Spike Protein From an Advanced Vaccine Candidate,” shows that the HEK293 aborted fetal cell line was used in the testing phase. The HEK293 cell line was originally harvested from the kidney of an aborted baby girl in 1973.
In a letter obtained by the Charlotte Lozier Institute, Novavax admits that HEK293 cells were indeed used as part of the testing phase for NVX-CoV2373:
“Testing was conducted to compare the structural integrity of the SARS-CoV-2 spike protein produced in the Sf9 insect cells versus the spike protein produced in the mammalian human embryonic kidney HEK 293F cells. The comparison determined the Sf9 cell technology produced spike proteins were comparable in structural integrity as the spike proteins produced in the HEK 293F cell.”
The Novavax shot, like mRNA COVID injections, has also demonstrated increased risk for heart inflammation. Several cases of myocarditis and pericarditis were observed in the trial participants within two weeks of injection.
Similar to Moderna and BioNTech, Novavax has never successfully brought a product to market in its 33-year history. The company has zero track record of success, safety, and/or efficacious products.
Novavax and the FDA panel have already stated that two doses of the Novavax shot will not be enough to “protect” people from the virus and repeated boosting will be necessary. The shot was developed over two years ago, but there is no trial data on the Omicron variant.
The FDA said: “Relevant data to assess effectiveness of NVX-CoV2373 (Novavax shot) against the Omicron variant and sublineages, including observational data from use in other countries where the vaccine has been deployed, are currently unavailable.”
Liberty Counsel Founder and Chairman Mat Staver said, “Novavax used aborted fetal cell lines in the testing phase, and it is already known that Novavax increases the risk of myocarditis. But the FDA continues to rubber stamp pharmaceutical companies with no history of success so long as the product is associated with COVID-19. The FDA is supposed to be the watchdog to protect public health, but, sadly, the FDA has become the lapdog of Big Pharma.”
“Because sentence against an evil work is not executed speedily, therefore the heart of the sons of men is fully set in them to do evil.” Ecclesiastes 8:11.